MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials
- PMID: 15110883
- DOI: 10.1016/j.ejca.2004.01.028
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials
Abstract
Cancer patients, especially the elderly, present with a highly variable susceptibility to toxicity from chemotherapy. To estimate correctly a patient's risk for toxicity, both the average toxicity of a chemotherapy regimen and patient-related variables need to be assessed. However, treatment toxicities are typically reported item by item, not summarised per patient. We tested an index derived from a pilot study, the MAX2, on the ECOG database. Studies including 20 or more patients aged 70 years and older per arm were selected. Four studies were identified, representing 2526 patients, 410 (16%) being elderly. The association of the MAX2 index with the per patient incidence of grade 4 haematological and/or grade 3 or 4 non-haematological toxicity was highly significant, both for the overall group and for the elderly subgroup. The MAX2 index is a convenient and reproducible way of comparing the average per patient risk for toxicity from chemotherapy across several regimens.
Similar articles
-
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.J Clin Oncol. 2007 Aug 20;25(24):3699-704. doi: 10.1200/JCO.2007.10.9710. J Clin Oncol. 2007. PMID: 17704418 Clinical Trial.
-
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.Cancer. 2012 Jul 1;118(13):3377-86. doi: 10.1002/cncr.26646. Epub 2011 Nov 9. Cancer. 2012. PMID: 22072065
-
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):672-8. doi: 10.1016/j.ijrobp.2008.05.020. Epub 2008 Nov 5. Int J Radiat Oncol Biol Phys. 2009. PMID: 18990504 Clinical Trial.
-
Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.Cancer Treat Rev. 2004 Jun;30(4):359-68. doi: 10.1016/j.ctrv.2003.12.006. Cancer Treat Rev. 2004. PMID: 15145510 Review.
-
Greater risks of chemotherapy toxicity in elderly patients with cancer.J Support Oncol. 2003 Nov-Dec;1(4 Suppl 2):18-24. J Support Oncol. 2003. PMID: 15346996 Review.
Cited by
-
Epigenetic Regulation of Inflammatory Mechanisms and a Psychological Symptom Cluster in Patients Receiving Chemotherapy.Nurs Res. 2023 May-Jun 01;72(3):200-210. doi: 10.1097/NNR.0000000000000643. Epub 2023 Mar 17. Nurs Res. 2023. PMID: 36929768 Free PMC article.
-
Gastrointestinal Symptom Cluster is Associated With Epigenetic Regulation of Lymphotoxin Beta in Oncology Patients Receiving Chemotherapy.Biol Res Nurs. 2023 Jan;25(1):51-64. doi: 10.1177/10998004221115863. Epub 2022 Aug 5. Biol Res Nurs. 2023. PMID: 35929442 Free PMC article.
-
An Evaluation of the Multifactorial Model of Cancer-Related Cognitive Impairment.Nurs Res. 2023 Jul-Aug 01;72(4):272-280. doi: 10.1097/NNR.0000000000000660. Epub 2023 Apr 24. Nurs Res. 2023. PMID: 37104681 Free PMC article.
-
Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways.J Neural Transm (Vienna). 2025 Feb;132(2):275-286. doi: 10.1007/s00702-024-02824-9. Epub 2024 Sep 26. J Neural Transm (Vienna). 2025. PMID: 39325169 Free PMC article.
-
Sleep disturbance is associated with perturbations in immune-inflammatory pathways in oncology outpatients undergoing chemotherapy.Sleep Med. 2023 Jan;101:305-315. doi: 10.1016/j.sleep.2022.11.014. Epub 2022 Nov 21. Sleep Med. 2023. PMID: 36470166 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources